

Satoshi Tamada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5794755/publications.pdf>

Version: 2024-02-01

33
papers

3,600
citations

516710

16
h-index

454955

30
g-index

34
all docs

34
docs citations

34
times ranked

4679
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study. <i>International Journal of Clinical Oncology</i> , 2022, 27, 154-164.	2.2	16
2	Pathologic complete response with pembrolizumab plus axitinib in metastatic renal cell carcinoma. <i>International Cancer Conference Journal</i> , 2022, 11, 205-209.	0.5	2
3	Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4513-4513.	1.6	3
4	Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4500-4500.	1.6	75
5	Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study. <i>International Journal of Clinical Oncology</i> , 2020, 25, 486-494.	2.2	10
6	Editorial Comment to Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study. <i>International Journal of Urology</i> , 2020, 27, 1100-1101.	1.0	0
7	Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1563-1573.	10.7	466
8	Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer. <i>Cancer Letters</i> , 2020, 479, 89-99.	7.2	36
9	Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5001-5001.	1.6	50
10	A pooled analysis of the efficacy and safety of cabozantinib post immunotherapy in patients with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5089-5089.	1.6	5
11	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1116-1127.	27.0	2,319
12	Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study. <i>International Journal of Clinical Oncology</i> , 2019, 24, 848-856.	2.2	14
13	Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4500-4500.	1.6	85
14	Outcomes of indwelling metallic stents for malignant extrinsic ureteral obstruction. <i>International Journal of Urology</i> , 2018, 25, 258-262.	1.0	25
15	Kamikihito improves cancer-related fatigue by restoring balance between the sympathetic and parasympathetic nervous systems. <i>Prostate International</i> , 2018, 6, 55-60.	2.3	11
16	Notch Signaling Enhances Stemness by Regulating Metabolic Pathways Through Modifying p53, NF- κ B, and HIF-1 α . <i>Stem Cells and Development</i> , 2018, 27, 935-947.	2.1	32
17	Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy. <i>Journal of Clinical Medicine</i> , 2018, 7, 444.	2.4	17
18	Treatment outcomes of ureteral stenting for malignant extrinsic ureteral obstruction: a comparison between polymeric and metallic stents. <i>Cancer Management and Research</i> , 2018, Volume 10, 2977-2982.	1.9	16

#	ARTICLE	IF	CITATIONS
19	Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma. <i>International Journal of Clinical Oncology</i> , 2018, 23, 944-950.	2.2	7
20	18-Fluoride-labeled sodium fluoride positron emission tomography is effective for assessing the therapeutic effect of Radium 223; a case report. <i>Urology Case Reports</i> , 2018, 19, 31-33.	0.3	0
21	A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer. <i>Basic and Clinical Andrology</i> , 2018, 28, 9.	1.9	7
22	Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer. <i>Oncotarget</i> , 2018, 9, 36966-36974.	1.8	26
23	Comparative effectiveness of radical prostatectomy and curative radiotherapy in localized prostate cancer: long-term follow-up. <i>Journal of Radiation Research</i> , 2016, 58, 552-558.	1.6	6
24	Anti- PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma. <i>Cancer Science</i> , 2016, 107, 1736-1744.	3.9	56
25	DDX39 acts as a suppressor of invasion for bladder cancer. <i>Cancer Science</i> , 2012, 103, 1363-1369.	3.9	27
26	Cobalt Protoporphyrin Attenuates Rat Obstructive Nephropathy: Role of Cellular Infiltration. <i>Urology</i> , 2008, 72, 432-438.	1.0	13
27	Attenuation of renal fibrosis by curcumin in rat obstructive nephropathy. <i>Urology</i> , 2006, 67, 440-446.	1.0	57
28	Molecular Mechanisms and Therapeutic Strategies of Chronic Renal Injury: The Role of Nuclear Factor Î^{B} Activation in the Development of Renal Fibrosis. <i>Journal of Pharmacological Sciences</i> , 2006, 100, 17-21.	2.5	52
29	Inhibition of nuclear factor- Î^{B} activation by pyrrolidine dithiocarbamate prevents chronic FK506 nephropathy. <i>Kidney International</i> , 2003, 63, 306-314.	5.2	47
30	Role of Renin-Angiotensin System and Nuclear Factor- Î^{B} in the Obstructed Kidney of Rats With Unilateral Ureteral Obstruction. <i>The Japanese Journal of Pharmacology</i> , 2002, 90, 361-364.	1.2	15
31	Magnesium supplementation prevents experimental chronic cyclosporine a nephrotoxicity via renin-angiotensin system independent mechanism.. <i>Transplantation</i> , 2002, 74, 784-791.	1.0	53
32	ROLE OF HYPOMAGNESEMIA IN CHRONIC CYCLOSPORINE NEPHROPATHY1. <i>Transplantation</i> , 2002, 73, 340-347.	1.0	52
33	Kamikihito improves cancer-related fatigue in castration-resistant prostate cancer patients receiving enzalutamide: Multidimensional approach including metabolomics analysis. <i>Traditional & Kampo Medicine</i> , 0, , .	0.6	0